Literature DB >> 11123042

Paget's disease of bone: diagnosis and treatment update.

M Noor1, D Shoback.   

Abstract

Paget's disease is a metabolic bone disease characterized by excessive bone resorption and formation due to activated osteoclasts. Although Paget's disease is a high bone turnover state, the excess bone that is formed lacks the structural stability of normal bone. Complications from Paget's disease include deformity, fracture, and pain. Although still unclear, both prevalence and severity of Paget's disease seem to be declining. Recent progress has focused on the environmental as well as genetic etiologies for this disease. Many studies indicate a role for viral infectious agents, whereas others point to a recently identified candidate gene on chromosome 18q. Therapy with bisphosphonate drugs is the treatment of choice. With newer and more powerful agents from this family now available, the majority of patients affected by Paget's disease can achieve sustained remission and avoid complications.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11123042     DOI: 10.1007/s11926-996-0071-x

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  48 in total

1.  Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: implications for the vascular control of bone resorption.

Authors:  A S Alam; A Gallagher; V Shankar; M A Ghatei; H K Datta; C L Huang; B S Moonga; T J Chambers; S R Bloom; M Zaidi
Journal:  Endocrinology       Date:  1992-06       Impact factor: 4.736

2.  Magnetic resonance imaging in symptomatic Paget's disease.

Authors:  G A Kaufmann; M Sundaram; D J McDonald
Journal:  Skeletal Radiol       Date:  1991       Impact factor: 2.199

Review 3.  Paget's disease of bone: clinical, pathogenetic and therapeutic aspects.

Authors:  S E Papapoulos
Journal:  Baillieres Clin Endocrinol Metab       Date:  1997-04

4.  On a Form of Chronic Inflammation of Bones (Osteitis Deformans).

Authors:  J Paget
Journal:  Med Chir Trans       Date:  1877

5.  Parathyroid function in Paget's disease of bone.

Authors:  E S Siris; T P Clemens; D McMahon; A Gordon; T P Jacobs; R E Canfield
Journal:  J Bone Miner Res       Date:  1989-02       Impact factor: 6.741

6.  Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone.

Authors:  E Siris; R S Weinstein; R Altman; J M Conte; M Favus; A Lombardi; K Lyles; H McIlwain; W A Murphy; C Reda; R Rude; M Seton; R Tiegs; D Thompson; J R Tucci; A J Yates; M Zimering
Journal:  J Clin Endocrinol Metab       Date:  1996-03       Impact factor: 5.958

7.  Evidence for secular change in Paget's disease.

Authors:  T Cundy; K McAnulty; D Wattie; G Gamble; M Rutland; H K Ibbertson
Journal:  Bone       Date:  1997-01       Impact factor: 4.398

8.  Interleukin-6, IL-6 receptor, and IL-6 nuclear factor gene expression in Paget's disease.

Authors:  J A Hoyland; A J Freemont; P T Sharpe
Journal:  J Bone Miner Res       Date:  1994-01       Impact factor: 6.741

Review 9.  Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired clinical resistance.

Authors:  F R Singer; R S Fredericks; C Minkin
Journal:  Arthritis Rheum       Date:  1980-10

10.  Macrophage colony-stimulating factor and interleukin-1 alpha maintain the survival of osteoclast-like cells.

Authors:  E Jimi; T Shuto; T Koga
Journal:  Endocrinology       Date:  1995-02       Impact factor: 4.736

View more
  2 in total

1.  Silent swelling of the tibia in a 43-year-old man.

Authors:  Ali Ocguder; Osman Tecimel; Ahmet Firat; Murat Bozkurt
Journal:  Clin Orthop Relat Res       Date:  2008-02-14       Impact factor: 4.176

2.  Radiological features of Paget disease of bone associated with VCP myopathy.

Authors:  Farzin Farpour; Jamshid Tehranzadeh; Sandra Donkervoort; Charles Smith; Barbara Martin; Pari Vanjara; Kathryn Osann; Virginia E Kimonis
Journal:  Skeletal Radiol       Date:  2011-06-04       Impact factor: 2.199

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.